KALEIDO BIOSCIENCES, INC. 5,250,000 Shares of Common Stock Underwriting AgreementKaleido Biosciences, Inc. • February 8th, 2021 • Biological products, (no disgnostic substances) • New York
Company FiledFebruary 8th, 2021 Industry JurisdictionKaleido Biosciences, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 5,250,000 shares of common stock, $0.001 par value per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 787,500 shares of common stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.